Katana PV
Ross I
Kiconco BE
Tenywa P
Neuman M
Ssembajjwe W
Sekitoleko I
Katumba KR
Kinyanda E
Laurence YV
Greco G
Health Policy Plan. 2026;
Between 8-39% of people living with HIV (PLWH) in sub-Saharan Africa have a depressive disorder (DD). Despite considerable gains in the treatment of PLWH, DD is increasingly recognised as a threat to successful treatment and prevention. PLWH incur higher health-related costs than the general population due to chronic care management needs. We aimed to estimate the combined economic burden of DD and HIV amongst PLWH and explore their mechanisms of coping with high out of pocket (OOP) health expenditure. This was a cost of illness study nested in a cluster-randomised trial that assessed the effectiveness of integrating treatment of DD into routine HIV care in Uganda (HIV+D trial). The study used cross-sectional data collected from 1,115 PLWH across both trial arms at baseline, using the Patient Health Questionnaire (PHQ-9) to measure DD and a structured cost questionnaire. The mean monthly economic cost of HIV and DD amongst n=486 participants reporting at least one non-zero cost item was USD 11.72 (2022 prices), while the mean across the whole sample (including zeroes) was USD 5.05. Mean monthly OOP expenditure amongst participants reporting at least one non-zero item was USD 7.22, which is 4% of average monthly household income. It was USD 3.11 in the sample as a whole. Moderate DD symptoms (PHQ-9 between 15-19) and severe symptoms (PHQ-920) were reported by 30% and 5% of respondents respectively, with the remainder experiencing mild symptoms. Social protection mechanisms combined with the integration of the management of DD into routine HIV care could help alleviate this burden.
